Company news

Propanc Biopharma, Inc. (NASDAQ:PPCB) news

Propanc Biopharma, Inc. news releases on 6ix. Latest, Sep 29, 2026: Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Propanc Biopharma, Inc. (NASDAQ:PPCB) news

Press releases & updates

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.

Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest

Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America

Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office

Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study

Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office

Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities